MacroGenics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on antibody-based cancer therapies, announced its management's participation in several upcoming investor conferences. Key events include:

• Stifel 2023 Targeted Oncology Days: Presentation by Scott Koenig on April 26, 2023, at 2:00 pm ET.
• H.C. Wainwright BioConnect Investor Conference: Fireside chat with Scott Koenig on May 2, 2023, at 1:00 pm ET.
• JMP Securities Life Sciences Conference: Fireside chat with Scott Koenig on May 15, 2023, at 9:30 am ET.

Investors can access webcasts of these presentations in the Investor Relations section of MacroGenics' website, with archived replays available for 30 days. The company utilizes advanced antibody technology to develop innovative therapeutics.

ROCKVILLE, MD, April 24, 2023 (GLOBE NEWSWIRE) -- MacroGenics, Inc. (Nasdaq: MGNX), a biopharmaceutical company focused on developing and commercializing innovative antibody-based therapeutics for the treatment of cancer, today announced that the Company's management will participate in the following upcoming investor conferences:

• Stifel 2023 Targeted Oncology Days (Virtual). Scott Koenig, M.D., Ph.D., MacroGenics’ President and CEO, will participate in a formal presentation on Wednesday, April 26, 2023, at 2:00 pm ET. MacroGenics’ management will also participate in one-on-one meetings. 
• H.C. Wainwright BioConnect Investor Conference at NASDAQ (New York). Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Tuesday, May 2, 2023, at 1:00 pm ET. MacroGenics’ management will also participate in one-on-one meetings.
• The JMP Securities Life Sciences Conference (New York). Scott Koenig, M.D., Ph.D., will participate in a fireside chat on Monday, May 15, 2023, at 9:30 am ET. MacroGenics’ management will also participate in one-on-one meetings.

Webcasts of the above presentations may be accessed under "Events & Presentations" in the Investor Relations section of MacroGenics' website at http://ir.macrogenics.com/events.cfm.  The Company will maintain archived replays of these webcasts on its website for 30 days.   

About MacroGenics, Inc.
MacroGenics (the Company) is a biopharmaceutical company focused on developing and commercializing innovative monoclonal antibody-based therapeutics for the treatment of cancer. The Company generates its pipeline of product candidates primarily from its proprietary suite of next-generation antibody-based technology platforms, which have applicability across broad therapeutic domains. The combination of MacroGenics' technology platforms and protein engineering expertise has allowed the Company to generate promising product candidates and enter into several strategic collaborations with global pharmaceutical and biotechnology companies. For more information, please see the Company's website at www.macrogenics.com. MacroGenics and the MacroGenics logo are trademarks or registered trademarks of MacroGenics, Inc.

###

FAQ

What conferences will MacroGenics (MGNX) participate in April and May 2023?

MacroGenics will participate in the Stifel 2023 Targeted Oncology Days on April 26, the H.C. Wainwright BioConnect Investor Conference on May 2, and the JMP Securities Life Sciences Conference on May 15, 2023.

Who is presenting for MacroGenics at these conferences?

Scott Koenig, M.D., Ph.D., President and CEO of MacroGenics, will be presenting at all three conferences.

Where can I watch the presentations from MacroGenics (MGNX)?

The presentations can be accessed via webcasts in the Investor Relations section of MacroGenics' website.

Is there an archive for the MacroGenics conference webcasts?

Yes, MacroGenics will maintain archived replays of the webcasts for 30 days after the events.

What is the focus of MacroGenics' therapeutic development?

MacroGenics focuses on the development of innovative monoclonal antibody-based therapeutics for cancer treatment.